TORONTO, Ontario, Sept. 06, 2024 (GLOBE NEWSWIRE) — Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce the filing and mailing of its management information circular (the “Circular”) with respect to the amalgamation agree
“The Circular sets out a compelling case for shareholders to approve Titan’s reverse merger with Conavi,” commented Paul Cataford, Titan’s Interim CEO and Board Chair. “After a thorough review of a number of potential transaction partners, Conavi came out on top. We believe the proposed Transaction offers our current Shareholders an opportunity to partially own an exciting commercial-stage company. Our financial advisors have provided a written opinion on the fairness of the relative valuation and the board of directors of Titan is recommending that all shareholders vote in favour of this Transaction.” Read More